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Disease-modifying effects of metabolic
perturbations in ALS/FTLD
Ali Jawaid1,2* , Romesa Khan2, Magdalini Polymenidou3† and Paul E. Schulz4†
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are two fatal neurodegenerative
disorders with considerable clinical, pathological and genetic overlap. Both disorders are characterized by the
accumulation of pathological protein aggregates that contain a number of proteins, most notably TAR DNA
binding protein 43 kDa (TDP-43). Surprisingly, recent clinical studies suggest that dyslipidemia, high body mass
index, and type 2 diabetes mellitus are associated with better clinical outcomes in ALS. Moreover, ALS and FTLD
patients have a significantly lower incidence of cardiovascular disease, supporting the idea that an unfavorable
metabolic profile may be beneficial in ALS and FTLD. The two most widely studied ALS/FTLD models, super-oxide
dismutase 1 (SOD1) and TAR DNA binding protein of 43 kDA (TDP-43), reveal metabolic dysfunction and a positive
effect of metabolic strategies on disease onset and/or progression. In addition, molecular studies reveal a role for
ALS/FTLD-associated proteins in the regulation of cellular and whole-body metabolism. Here, we systematically
evaluate these observations and discuss how changes in cellular glucose/lipid metabolism may result in abnormal
protein aggregations in ALS and FTLD, which may have important implications for new treatment strategies for
ALS/FTLD and possibly other neurodegenerative conditions.
Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disorder that is characterized by the progressive
degeneration of both upper and lower motor neurons,
which results in a multitude of motor symptoms, including
muscle weakness, fasciculations, spasticity, dysphagia, and
eventually respiratory dysfunction [167]. There is also an
established clinical overlap between ALS and frontotem-
poral lobar degeneration (FTLD). FTLD is a pathological
diagnosis that manifests clinically in the form of fronto-
temporal dementia (FTD), which is characterized by
cognitive, behavioral, and linguistic dysfunction. Almost
50% of ALS patients show cognitive impairment of the
type observed in FTD, with 15% of ALS cases meeting
diagnostic criteria for FTD at the time ALS is diagnosed
[144]. In addition, 15% of FTLD cases have clinically
detectable motor symptoms [92]. Ten percent of all ALS
patients, and one third of all FTLD patients, have a positive
family history with at least one immediate family member
having the disease [92, 119]. The prevalence (62%) and pat-
tern (related to FTD) of cognitive impairment in familial
ALS are similar to that of sporadic ALS [183].
Like many neurodegenerative diseases, ALS and FTLD
are associated with the abnormal aggregation of specific
proteins in neurons and glia. Superoxide dismutase 1
(SOD1) was the first aggregated protein to be associated
with ALS, just over two decades ago [147]. Since then,
several other proteins have been shown to form abnormal
neuronal aggregates in ALS and FTLD, including TAR
DNA binding protein 43 kDa (TDP-43) and fused in
sarcoma (FUS). According to the predominant type of
aggregated protein found, ALS is classified as ALS-
TDP, ALS-FUS, or ALS-SOD; and FTLD as FTLD-Tau,
FTLD-TDP, FTLD-FUS, or FTLD-UPS (for Ubiquitin-
Proteasome system) [102]. Among these subtypes,
ALS-TDP and FTLD-TDP are the most common, repre-
senting 98% of ALS and 45% of FTLD cases, and are the
most important indicator that there is a pathophysio-
logical continuum between the two disorders [92].
The molecular mechanisms that underlie abnormal neur-
onal protein aggregation in ALS/FTLD remain unknown,
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but mutations in several genes can trigger the formation of
such aggregates. TDP-43 aggregates result from mutations
in the TARDBP gene, as well as from mutations in pro-
granulin (PGRN), chromosome 9 open reading frame
72 (C9ORF72), valosin-containing protein (VCP), p62/
sequestosome (SQSTM1), optineurin (OPTN), chroma-
tin modifying protein 2B (CHMP2B), and Ubiquilin 2
(UBQLN2). Similarly, FUS protein aggregates result from
mutations in the FUS gene, as well as in TATA-binding
protein-associated factor 15 (TAF15), and Ewing’s
sarcoma breakpoint region 1 (EWSR1) [101]. Notably,
abnormal aggregates are present in all ALS/FTLD cases
even when no genetic mutations are present. As discussed
later, the causes of neuronal death in ALS/FTLD are
also unknown and are being investigated in animal
models, with studies supporting a role for oxidative dam-
age, excitotoxicity, and apoptosis [46, 110, 132, 170].
Clinical and epidemiological studies have identified a
number of risk factors and disease-modifiers that can
impact the clinical course in ALS and FTLD, including
metabolic parameters. Notably, a conventionally ‘risky’
cardiovascular profile, such as a high body mass index
(BMI), or diabetes mellitus type 2, might protect individuals
from ALS by delaying the onset of symptoms and/ or slow-
ing clinical progression, whereas, a ‘beneficial’ cardiovascular
profile, with a low body mass index, an athletic lifestyle, and
low blood cholesterol levels, may increase the risk or worsen
the prognosis [77]. This intriguing relationship between
metabolism, ALS and FTLD warrants a thorough evalu-
ation of the rapidly accumulating clinical evidence on
the topic, as well as, exploration of molecular data that
could reveal their biological underpinnings and suggest
new treatment strategies.
In this review, we discuss the disease-modifying effects
of metabolic disorders in ALS/FTLD and the preclinical
studies that demonstrate the involvement of ALS- and
FTLD-associated genes/proteins in metabolic pathways.
Moreover, we present several hypotheses as to how
metabolic perturbations may modulate pathological protein
aggregation or its consequences in ALS and FTLD. We con-
clude by discussing a potential disease-modifying effect of
metabolic disorders in other neurodegenerative disorders.
The disease-modifying effects of metabolic
disorders in ALS
Table 1 summarizes studies suggesting a protective role
for traditionally “risky” cardiovascular profiles in ALS
and FTLD.
Dyslipidemia
Dyslipidemia appears to be protective in ALS, both in
terms of improved prognosis and reduced risk of the
disease. An abnormally high low-density lipoprotein (LDL)/
high-density lipoprotein (HDL) ratio is associated with an
increase in survival by 12months in ALS [n = 369, [47]].
Similarly, triglycerides above 1.47mmol/L prolong survival
in ALS patients by 14months [n = 488, [44]]. Furthermore,
antecedent hyperlipidemia delays ALS onset [n = 1439,
[67]]. This association is further supported by studies dem-
onstrating that a conventionally ‘favorable’ vascular profile,
including hypolipidemia, increase the risk of ALS. Some-
times, this in a gender-dependent fashion with only male
ALS patients having significantly lower total cholesterol and
triglycerides than male controls [166, 191].
The effect of dyslipidemia on ALS survival could be
confounded by other factors, such as body mass index
[BMI, [124]]. Rafiq et al. showed a beneficial effect of
dyslipidemia on survival in a cohort of ALS patients
(n = 512) enrolled in the Olesoxime (a neuroprotective
compound) phase II-III clinical trial for ALS treatment;
however, the statistical significance was lost when adjusted
for age of onset, or BMI [140]. Similarly, Dedic et al.
observed an approximately 8 month longer survival in
ALS patients (n = 82) who have dyslipidemia compared
to those without dyslipidemia, but it was not statistically
significant [35]. Both studies, however, included a remark-
ably higher proportion of ALS patient with dyslipidemia
(64% in Rafiq et al. and 52% in Dedic et al.) than has been
reported for other ALS cohorts (around 40% in Hollinger
et al.), raising a question about the generalizability of these
results.
Diabetes mellitus
Some earlier reports suggested that ALS patients might
have certain features of diabetes mellitus (DM), such as
glucose intolerance [143]. More recent studies have shown a
considerate influence of diabetes mellitus on ALS risk and
prognosis. Insulin-dependent Type 1 DM (T1DM) appears
to increase the risk of ALS 5.83 times (OR: 1.87–15.51,
[105]). In stark contrast, however, Type 2 DM (T2DM),
a form of insulin-independent DM, appears to have a
beneficial effect on the course of ALS in terms of a reduced
risk and better prognosis [74, 77]. A likely explanation for
contrasting effects of T1DM and T2DM on ALS could be
the different etiopathogenesis of the diseases. In contrast to
TD2M, T1DM is an autoimmune disorder, and they are
known to increase the risk of ALS [171].
A Swedish ALS cohort (n = 5108) showed an inverse
association (OR: 0.66, 95% CI 0.53–0.81) between non-
insulin dependent DM (likely T2DM) and the risk of
ALS [105]. Two different American cohorts have also
reported a reduced prevalence of T2DM in ALS patients,
suggesting that T2DM might reduce the risk of ALS
[111, 125]. In our large study of 2371 patients, pre-morbid
T2DM, i.e., occurring before onset of ALS symptoms, was
associated with a four-year delay in ALS onset and a
prolonged survival of about six months [75]. Another
study showed a trend (p < 0.1) towards slower disease
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progression in ALS patients with pre-morbid T2DM
[74, 125]. Finally, a recent study investigated for ALS
occurrence in all residents of Turin (n = 727,977) who
were 14 years of age at 1996 during an assessment
period from 1998 to 2014. During this period, 397 patients
developed ALS and diabetes was found to decrease the
risk (hazard ratio: 0.30, 95% CI 0.19–0.45) of ALS occur-
rence [32]. A Taiwanese study, however, did not show a
link between T2DM and ALS [165]. Similarly, an as-
sessment of the association with baseline HbA1c and
survival in Chinese ALS patients (n = 450) showed that
increased baseline HbA1c was associated with in-
creased risk of mortality [182]. These discrepant results
in Asian ALS patients raise the possibility that the pro-
tective effect of T2DM on ALS could depend on ethni-
city [97].
Body weight
The association between body weight and ALS is very
interesting. Several studies have shown that a low
(under-weight) pre-morbid body mass index (BMI) is a
risk factor for ALS ([72, 104, 116, 122]). At the other
end of the spectrum, several studies have shown that a
high (over-weight or obese) BMI at diagnosis is associated
with slower disease progression and decreased mortality in
ALS [56, 141]. In another ALS cohort (n = 285), the rate of
symptom progression was inversely related to changes in
BMI during the first year after ALS diagnosis [76]. Other
studies have also demonstrated that a decrease in BMI after
onset of motor symptoms dramatically reduces survival in
ALS patients [125, 157]. Collectively, these studies
strongly suggest an association between lower body
weight and ALS risk, and a worse prognosis in patients with
faster weight loss after ALS diagnosis.
Physical activity
Physical activity is an important determinant of metabolic
homeostasis and hence may be very relevant to ALS risk.
Several studies, in fact, report that high levels of physical
activity and/or an athletic lifestyle significantly increase
the risk and/or worsen the prognosis of ALS [11, 25, 72,
98, 123, 169]. However, not all studies have come to this
conclusion [173, 177], and one study suggests that exer-
cise and high levels of physical activity may even be
Table 1 Clinical studies finding associations between metabolic diseases or risk factors and ALS/ FTLD risk or prognosis
Metabolic condition Evidence supporting a beneficial effect
on risk/prognosis of ALS
Evidence not supporting a beneficial
effect on risk/ prognosis of ALS
Citation, sample size (n)
Dyslipidemia Increased survival in ALS by 12.5 months N/A Dupuis et al. [47] (n = 369 ALS,
n = 286 controls)
Increased survival in ALS by 14 months Dorst et al. [44] (n = 488 ALS)
Increased survival in ALS by 5.8 months Huang et al. [70] (n = 413 ALS)
Delay in ALS onset by almost 6 years Hollinger et al. [67] (n = 1439 ALS)
N/A Increased survival in ALS confounded
by BMI
Paganoni et al. [124] (n = 427 ALS)
Increased survival in ALS confounded
by age and BMI
Rafiq et al. [140] (n = 512 ALS)
Increased survival in ALS not significant Dedic et al. [35] (n = 82 ALS)
T2DM Delay in ALS onset by 4 years N/A Jawaid et al. [75, 76] (n = 2371 ALS)
Decreased risk of ALS in non-insulin
dependent T2DM
Mariosa et al. [105] (n = 5108 ALS,
n = 25,540 controls)
Decreased prevalence of T2DM in ALS Paganoni et al. [125]
Decreased prevalence of T2DM in ALS Mitchell et al. [111] (n = 1288 ALS,
n = 7561 controls)
Decreased risk of ALS in people with DM D’Ovidio et al. [32] (n = 727,977)
N/A No association between T2DM
and ALS risk
Sun et al. [165] (n = 615,492 diabetics,
n = 614,835 controls)
Increased mortality in ALS patients
with high baseline HbA1c
Wei et al. [182]
(n = 450 ALS)
High BMI Increase in BMI slowed functional decline
in ALS
N/A Jawaid et al. [75, 76] (n = 285 ALS)
High BMI slowed progression and
decreased mortality in ALS
Gallo et al. [56] (n = 518,108 over-all)
Reich-Slotky et al. [141] (n = 150 ALS)
Cardiovascular diseases Decreased risk of FTLD N/A Kalkonde et al. [80] (n = 63 FTD,
n = 491 non-FTD dementias)
Abbreviations: BMI body mass index, T2DM type 2 diabetes mellitus, N/A not applicable
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beneficial, with overall physical activity associated with a
reduced odds (OR = 0.56, 95% CI: 0.36–0.87) of having
ALS [138].
It is possible that this wide variability in outcomes is
related to the fact that almost all of these studies have been
retrospective. A recent Cochrane systematic review on the
role of exercise on ALS risk and progression identified a
lack of comparable outcome parameters in retrospective
studies, as well as a lack of prospective analyses as likely
reasons for these conflicting results [33]. The first prospect-
ive study (n = 472,100) reported a borderline significantly
(p = 0.042) decreased risk of dying (HR = 0.67, 95% CI:
0.42–1.06) from ALS in patients with high levels of physical
exercise at the time of enrollment [55]. However, a robust
case-control study of ALS patients (n = 1557) vs. matched
controls (n = 2992) recruited from five population-based
registries in The Netherlands, Ireland, and Italy revealed
a modest linear association between physical activity
and ALS risk ((OR: 1.06, p < 0.001), [179]). More pro-
spective analyses in future will likely clarify the association
between exercise and ALS.
Metabolic drugs
Clinical studies suggest that there is an intriguing relation-
ship between the use of drugs that treat common metabolic
conditions and the risk and rate of progression of ALS.
Despite rapidly emerging evidence that T2DM is pro-
tective in ALS, certain anti-diabetic drugs have been
used to treat ALS because of their anti-inflammatory
properties. Pioglitazone, which is used to manage T2DM,
enhanced the survival of a mouse SOD1 model of ALS;
however, a phase II clinical trial suggested that this drug
increased the risk of death in ALS patients, although this
increase lacked statistical significance [48, 77]). Collect-
ively, the results of these studies suggest caution in use
of drugs that are used to treat T2DM and dyslipidemia
in ALS patients.
Preliminary reports have suggested an increased occur-
rence of ALS among users of statins, which are used to treat
dyslipidemia [50]. However, more rigorous analyses have
subsequently found a null association between statins and
ALS risk (OR: 0.96, 95% CI: 0.73–1.28, [158]), as well as,
prognosis [45]. Similarly, other reports suggest that the asso-
ciation between statin use and risk of ALS could be gender-
dependent, with only female ALS patients on statins
showing a significantly faster decline (a decline of 3
points more over 12 months) in (ALS-functional rating
scale) ALS-FRS compared to those not on statins [118].
Diet-based trials for ALS treatment
The evidence that changes in BMI and metabolic pertur-
bations can alter the course of ALS has led to several trials
of diet-based treatment for this disease. A notable example
is a prospective interventional study (n = 26) that
compared a high-fat and high-carbohydrate diet in ALS,
which showed that both diets could stabilize or increase
the BMI of ALS patients [43]. However, this study did not
explore the effects of a stabilized BMI on disease pro-
gression or survival. In another placebo-controlled,
phase II trial (n = 26), mortality and disease progression
in ALS patients on a high calorie/high carbohydrate (HC/
HC) diet or on a high-calorie/high-fat (HC/HF) diet was
compared to mortality and disease progression in ALS
patients on a normal control diet. This trial found signifi-
cantly (p < 0.03) reduced mortality (p < 0.03) and a trend
towards slower ALS progression (p = 0.07), in the HC/HC
group versus controls [185].
Other studies also suggest beneficial effects (slower
progression and/ or longer survival) of nutritional coun-
seling [6], and of diets that contain omega-3 fatty acids
[53], anti-oxidants and carotenes [78, 121], acetyl carnitine
[12], and Vitamin E [54] in ALS. The role of Vitamin D,
however, remains unclear, with both its deficiency [20, 82]
and increased levels (-[15]) having been associated with
worse prognosis in ALS.
In conclusion, current evidence strongly supports a role
for dyslipidemia, T2DM, and obesity in reducing the risk
for acquiring ALS and improving its prognosis. A recent
study further showed an inverse association between
serum retinol binding protein-4 and ALS risk and progno-
sis. Serum retinol binding protein 4 indicates the overlap-
ping molecular manisfestaion of insulin resistance in
dyslipidemia/T2DM/obesity, and thus provides further
evidence for a protective effect of metabolic disorders in
ALS [148]. The evidence supporting a disease-modifying
effect of exercise and dietary regimens on ALS is, however,
less conclusive and warrants further investigations. There
is also evidence for a disease-modifying role of metabolic
disorders on the risk and prognosis of the closely related
disorder, FTLD.
The disease-modifying effect of metabolic
disorders in FTLD
The disease-modifying effects of metabolic disorders in
FTLD have not been well studied. However, in a large
cohort of military veterans with dementia (n = 554), the
risk of developing FTD was reduced (OR = 0.4, CI = 0.3–
0.96) in patients with cardiovascular disease [80]. A
study of 31 behavioral variant FTD patients and 19
controls found that behavioral FTD patients have con-
siderably higher (1.9 mmol/L) serum triglycerides than
controls (0.85mmol/L), which is a known cardiovascular
risk factor [3].
More studies are thus needed to ascertain whether
metabolic disorders have a protective effect on the pro-
gression of FTLD, similar to their effect on ALS. It is
also plausible that metabolic perturbations have con-
trasting effects on the motor and cognitive functioning
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of the brain. We found, for example, that T2DM has
contrasting effects on the motor and cognitive functions
of patients with ALS. Pre-morbid T2DM delayed the on-
set of motor symptoms in ALS patients, but impaired
frontal and temporal cognitive functioning [75]. Animal
models and neuropathological studies will certainly help
delineate these effects.
Evidence for metabolic dysfunction in ALS/ FTLD through
omics and biochemical assays
Mass-spectrometry based omics approaches present a
great opportunity for a wide-scale and robust investiga-
tion of a pathophysiological link between neurodegener-
ative and metabolic processes in ALS/ FTLD. An initial
metabolomics-based comparison between ALS patients
(n = 19) and controls (n = 33) found an increase in 6 me-
tabolites in the plasma of ALS patients, however the
study did not indicate their exact characteristics [149].
Another study showed an increase in 23 metabolites,
notably related to hypermetabolism, oxidative damage,
and mitochondrial dysfunction in the plasma of ALS pa-
tients (n = 62 + 99 for two different assessments) compared
to controls (n = 69 + 48 for two different assessments) [86].
Importantly, a number of these metabolites, such as Carni-
tine and Paraxanthine are also altered in T2DM and dyslip-
idemia, in the opposite direction [13, 172]. A third study
demonstrated changes in plasma tryptophan, arginine, and
proline metabolism pathways in the plasma of ALS patients
(n = 24) relative to age- and gender-matched controls (n =
24) [134]. Intriguingly, some of these metabolites, such as
Valine and Serine, again show an opposite expression in
dyslipidemia and T2DM [22, 113, 189]. More recent lipido-
mics analyses further reveal hypoalphalipoproteinemia and
increased CSF phosphatidylcholine as metabolic signatures
of bvFTD [84] and ALS [16] respectively.
In addition to metabolomics, other biochemical analyses
have also revealed peripheral metabolic signatures unique
to ALS. A study on peripheral lipoproteins revealed a char-
acteristic low IDL-B and high LDL-1 in the serum of ALS
patients [37]. Another study, which quantified 40 different
sterols, showed that (25R) 26-hydroxycholesterol, the im-
mediate precursor of 3β-hydroxycholest-5-en-26-oic acid,
was reduced in ALS patients compared with controls [2].
These analyses are very important additions to the afore-
mentioned clinical observations showing the effect of
metabolic disorders on ALS/ FTLD.
Metabolic dysfunction in animal models of ALS/FTLD
Another important approach to understanding and utilizing
metabolic changes in ASL/FTD are animal models where
one can control for many variables that are challenging in
humans.
SOD1 and TDP-43 are the most widely studied animal
models of ALS/FTLD, and there are several important
recent studies manipulating SOD1 and TDP-43 genes
(knock-out, conditional knock-out, knock-in, over-ex-
pression of the endogenous or human protein, mutations)
to decipher metabolic changes in these animals and utilizing
these findings for pre-clinical trials of metabolism-based
therapeutic strategies.
Metabolic dysfunction in the SOD1 model of ALS
Missense mutations in the Cu/Zn-binding superoxide
dismutase (SOD1) gene, which encodes a ubiquitously
expressed antioxidant enzyme, are reported in 10–20%
cases of familial ALS [38, 147]. Sod1 mutant mice develop
many pathological features of human ALS, including loss
of upper and lower motor neurons, progressive paralysis,
and the accumulation of ubiquitinated inclusions in the
neurons that contain misfolded Sod1 [59, 145].
SOD1 mice also exhibit signs of metabolic dysfunction,
including increased energy expenditures, skeletal muscle
hypermetabolism, and reduced adipose tissue, even at the
asymptomatic stage [49, 127]. This is followed by rapid
weight loss after symptom onset [62]. Furthermore, Sod1
mutant mice also exhibit wide-ranging deregulation of
their lipid metabolism, including peripheral hypolipidemia
[41, 52, 83] and upregulated levels of ceramides, glucosyl-
ceramides and glycosphingolipids [42, 64, 155].
The metabolic perturbations observed in Sod1 mutant
mice have prompted scientists to explore their therapeutic
potential. The administration of a high-fat, energy-rich diet
protected Sod1 mouse mutants against motor disease
progression [49, 52]. Similarly mitigating effects have been
reported following the treatment of Sod1 mouse mutants
with the triglyceride triheptanoin [168] or with a ganglio-
side, GM3 [42]. Switching mutant Sod1 mice from a nor-
mal to a ketogenic diet, or giving them caprylic triglyceride,
which is metabolized to ketone bodies, restored their
mitochondrial ATP production and was accompanied
by reduced neuronal loss, delayed onset of motor dysfunc-
tion, and enhanced survival [193, 194]. Arginine-alpha-
ketoglutarate supplementation also improved the motor
functions and lifespan of Sod1 mutant mice [7]. In con-
trast, caloric restriction in rodent models expressing
mutant Sod1, have shown detrimental effects, i.e. earlier
symptom onset and shortened lifespan [60, 61, 133].
Metabolic dysfunction in TDP-43 models
The presence of ubiquitinated and phosphorylated cyto-
plasmic inclusions of TDP-43 in the CNS of patients
with ALS and FTLD [119], and the subsequent identifi-
cation of TARDBP mutations in the sporadic and
familial forms of these diseases [57, 79, 160, 175, 192],
have led to the rapid development of TDP-43 trans-
genic models. Mutant Tardbp mice manifest some key
features of human ALS and FTLD, including motor
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neuron loss, gliosis, motor and cognitive deficits, and
early mortality [4, 5, 8, 18, 73, 162, 186, 188, 194].
As with the SOD-1 mutants, the TDP-43 rodent
models have demonstrated metabolic dysfunction. The
conditional neuromuscular knock-out [24, 190] of Tardbp
in mice led to a reduction in adipose tissue and weight
loss [24, 164]. This effect was mediated by depletion of the
protein Tbc1 domain family member 1 (Tbc1d1), which
regulates the translocation of glucose 4 transporter
(GLUT4) and energy homeostasis (reviewed in [152]) in
skeletal muscles, and which favored lipolysis and leanness.
Conversely, TDP-43 overexpression lead to elevated
Tbc1d1 in skeletal muscle, which was associated with
an increase in body fat and defective insulin-mediated
glucose uptake [161].
A recent study in TDP-43 mutant mice demonstrated
the beneficial effects of an energy-rich, high-fat jelly diet
in enhancing survival [29]. This was corroborated by the
protective effects of high sugar intake in a Caenorhabditis
elegans model of ALS that expresses mutant TDP-43 [1].
Similarly, supplementation with medium-chain fatty acids
and beta-hydroxy butyric acid, as well as genetic manipu-
lation of the carnitine shuttle, which is important to
mitochondrial transport of long-chain fatty acids, improves
motor functions in a drosophila model of ALS with mutant
TDP-43 over-expression [103].
Collectively, evidence from Sod1 and TDP-43 models
reveals a potential for metabolic, therapeutic intervention
strategies in ALS/FTLD. The next section addresses the
critical question of whether and how ALS/FTLD proteins
modify metabolism.
Role of ALS/FTLD-associated proteins in
metabolism
ALS/FTLD associated proteins may act directly to regulate
cellular and/or whole-body metabolism, which we review
here and in Table 2.
The TDP-43 protein
As noted, TDP-43 can regulate whole-body metabolism
and glucose transport through the obesity-related gene
Tbc1d1 [24, 161]. It is now known that the TARDBP
knock-in mice have increased serum levels of free fatty
acids and HDL cholesterol. This phenotype is accom-
panied by decreased expression of the gene encoding the
fatty acid transporter, CD36, and by the dysregulation of
a cluster of genes involved in energy production, lipid
metabolism, the respiratory electron transport chain and
various mitochondrial pathways [164].
In vitro, TARDBP regulates glycolysis in a hepatocellular
carcinoma cell line through the miRNA-mediated post-
transcriptional regulation of a key rate-limiting glycolytic
enzyme phosphofructokinase (PFKP) [131]. These studies
highlight an important role for TDP-43 in the regulation
of key metabolic processes, including glucose and lipid
transport and metabolism, and provide a basis for the
observed disease-modifying effect of metabolic dysfunction
in ALS and FTLD.
Progranulin
Haploinsufficient, loss-of-function mutations in the human
PGRN gene are found in 5–20% of patients with familial
FTLD and are a common cause of FTLD-TDP ([9, 30,
100]. Progranulin (PGRN) is an ~ 70 kDa, secreted protein
that is implicated in numerous cellular processes, from in-
flammation to wound healing [63, 187]. In the brain,
PGRN is believed to function as a neurotrophic factor
[150, 174].
Now, PGRN is known to have an important role in
lipid metabolism and insulin signaling. In contrast to its
pathogenic role in FTLD, Pgrn haploinsufficiency in mice
confers protection against diet-induced obesity and insulin
resistance [120]. Conversely, higher plasma levels of PGRN
have been found in patients with T2DM, which is character-
ized by insulin resistance [139]. Similarly, insulin resistance,
adipocyte hypertrophy and obesity result from perturbations
in the regulation of the inflammatory cytokines interleukin 6
(IL-6) and tumor necrosis factor α (TNF-α) in mice with
increased PGRN through Pgrn over-expression or adminis-
tration of recombinant PGRN [93, 95, 107, 196]. Further-
more, the administration of recombinant PGRN to wild
type mice leads to impaired insulin sensitivity [93, 95].
Trehalose, a natural disaccharide, has also been proposed
as a possible therapy for FTLD as it can restore wild type
levels of progranulin expression in Prgn haploinsufficient
mice [66]. Taken together, these studies suggest that
PGRN lies at the intriguing interface between metabolic
disorders and ALS/FTLD, whereby its deficiency is associ-
ated with neurodegeneration and its increase is associated
with metabolic perturbations.
The TREM2 protein
A missense variant of triggering receptor expressed on
myeloid cells 2 (TREM2) (p.R47H) was recently shown to
increase the risk of multiple NDDs, including Alzheimer’s
disease and ALS in genome-wide association studies
(GWAS). TREM2 is also associated with a poorer ALS
prognosis as higher spinal cord levels of TREM2 protein
in ALS patients correlate with reduced survival [19].
TREM2 is a 26 kDa transmembrane glycoprotein that is
involved in multiple inflammatory processes, including
microglia activation [195].
Recent animal studies have revealed that TREM2 can
regulate adipogenesis by inhibiting the Wnt10b/β-catenin
signaling pathway. This action stimulates adipogenesis by
increasing the glycogen synthase kinase-3β-mediated
phosphorylation of β-catenin, and by increasing adipocyte
differentiation through upregulation of the adipogenic
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transcription factors CCAAT-enhancer binding protein
alpha (C/EBPα) and peroxisome proliferative-activated
receptor gamma (PPARγ) [128, 129]. Accordingly, Trem2
over-expressing mice exhibit insulin resistance, adipocyte
hypertrophy, and hepatic steatosis [130]. Similarly to
PGRN and TDP-43, the metabolic functions of TREM2
seem to contribute to ALS: TREM2 deficiency is deleterious
in ALS, whereas TREM2 over-expression leads to various
features of metabolic syndrome that have been shown to be
favorable in ALS.
FET proteins
A family of RNA-binding proteins, called the FET proteins
(as the family members include FUS, EWS, and TAF15), is
important for RNA metabolism. They form abnormal
aggregates in ALS/ FTLD similar to TDP-43 [81, 126, 197].
TAF15 and EWS often co-aggregate with FUS in the
neurons and glia in most cases of FTLD-FUS but not in
ALS with FUS mutations [101].
As with other FTLD proteins, FUS and EWS may
also influence metabolic processes. An analysis of the
FUS interactome by mass spectrometry showed that
mutant FUS has an increased association with enzymes
involved in glucose metabolism, compared to wild-type
FUS [180]. Additionally, the over-expression of FUS
has been reported to significantly reduce ATP levels in
human neuroblastoma cells [180]. In HEK293 cells, the
accumulation of FUS protein upon FUS over-expression
reportedly limits Ca2+ availability in mitochondria, which
is essential for several enzymes of the TCA cycle [58],
resulting in decreased production of ATP [163]. In
another study, mislocalization of FUS to the mito-
chondria induced mitochondrial fragmentation in FUS-
overexpressing Drosophila melanogaster [39], which
explained the impaired mitochondrial bioenergetics ob-
served in these flies.
A similar decrease in mitochondrial density is seen in
mouse preadipocytes that are deficient for EWS. More-
over, a host of genes involved in mitochondrial respiration
and fatty acid β-oxidation were shown to be down-reg-
ulated in the liver of EWS knock-out mice [128, 129].
Similarly, EWS has been shown to regulate important
Table 2 Role of ALS/FTLD associated proteins in cellular or whole body metabolism
Protein Model Molecular manipulation Implication of the protein in metabolic pathways Citation
TDP-43 Mice Tardbp conditional
neuromuscular knock-out
Regulation of obesity-associated gene Tbc1d1 Chiang et al. [24]
Mice Tardbp neuromuscular
over-expression
Regulation of glucose transporter GLUT4 translocation Stallings et al. [161]
Mice Knock-in of human hTDP-43A315T Regulation of fatty acid transporter CD36 Stribl et al. [164]
HCC cell line TARDBP RNAi Regulation of rate-limiting enzyme of glycolysis PFKP Park et al. [131]
iPSC-derived neurons
from ALS/FTLD
Over-expression of disease-linked
TARDBP mutations
Disruption of mitochondrial complex I assembly by
TDP-43 pathological mis-localization in ALS/FTLD
Wang et al. [181]
PGRN Mice IP injections of recombinant
PGRN protein
Control of insulin-resistance, obesity, and adipose
tissue dynamics through IL-6 and TNF-α
Zhou et al. [196]
Mice IP injections of recombinant
PGRN protein
Regulation of insulin sensitivity through PERK-eIF2α axis Li et al. [90]
TREM2 Mice Trem2 over-expression Regulation of adipogenesis and adipocyte differentiation
through Wnt-1/β-Catenin signaling
Park et al. [128, 129]
Mice Trem2 over-expression Regulation of insulin resistance and hepatic steatosis Park et al. [130]
FUS Drosophila Mutant human FUS
over-expression
Fragmentation of mitochondria caused by pathological
aggregation of FUS to mitochondria
Deng et al. [39]
N2a cell line Mutant human FUS
over-expression
Mutant FUS interacts with enzymes involved in
glucose metabolism
Regulation of ATP production
Wang et al. [180]
NSC34 cell line Mutant human FUS
over-expression
Regulation of ATP production Stoica et al. [163]
EWS Mice EWS knock-out Regulation of mitochondrial density in pre-adipocytes Park et al. [128, 129]
C9ORF72 Motor neurons and lymphoblastoid cell lines from
ALS patients with C9ORF72 expansion
Regulation of genes involved in cholesterol
biosynthesis and glucose metabolism
Cooper-Knock et al. [27]
Abbreviations: TDP-43/ Tardbp Tat activating responsive DNA binding protein, PGRN Progranulin, TREM2/Trem2 Triggering receptor expressed on myeloid cells 2,
FUS/FUS Fused in sarcoma, EWS/EWS Ewing’s sarcoma, C9ORF72 Chromosome 9 open reading frame 72, HCC Hepatocellular carcinoma, iPSC induced pluripotent
stem cells, N2a Neuroblastoma, NSC34 Motor- neuron like cells, RNAi RNA interference, Tbc1d1 Tre-2/Bub2/Cdc16 1 domain family member 1, GLUT4 Glucose
transporter 4, CD36 cluster of differentiation 36, PFKP Phosphofructokinase, IL-6 Interleukin 6, TNF-α Tumor necrosis factor alpha, PERK Protein kinase RNA-like
endoplasmic reticulum kinase, eIF2α Eukaryotic initiation factor alpha
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metabolism-linked signaling pathways, such as Transform-
ing growth factor- beta (TGF-β) and Insulin-like growth fac-
tor- 1 receptor (IGF-1R) [26, 65, 109, 136]. Taken together,
these studies suggest that FET proteins, as with TDP43, are
involved in energy homeostasis. This hypothesis, however,
needs further investigation, especially in vivo.
The C9ORF72 protein
The discovery of mutations in the chromosome 9 open
reading frame 72 (C9orf72) gene provided the first genetic
and pathogenic link between ALS and FTLD [36, 142].
These mutations result in intronic GGGGCC hexanucleo-
tide repeat expansions, and are present in almost 40% of
familial and 10% of sporadic ALS cases characterized by
TDP-43 pathology [92]. An exon-array analysis showed that
C9orf72 repeat expansions lead to the differentially regu-
lated splicing of several genes involved in cholesterol biosyn-
thesis and glucose metabolism [27]. Recently, C9orf72-based
ALS/FTLD rodent models have been generated [94],
and it will be interesting to investigate whether alter-
ations in glucose and cholesterol metabolism are asso-
ciated, in these models, with disease severity.
Does metabolic dysfunction affect protein
aggregation in ALS and FTLD?
Both clinical and basic research, then, suggest the involve-
ment of metabolic processes in ALS/FTLD pathophysiology.
An vital question to address is whether the abnormal pro-
tein aggregation in ALS and FTLD occurs as a consequence
of changes in metabolism or vice versa. Here we propose
three plausible pathways by which changes in cellular or
whole-body metabolism may lead to protein aggregation in
ALS and FTLD (Fig. 1).
1. Physiological stress granules have been proposed to
act as precursors of abnormal TDP-43 and FUS
inclusions in ALS/FTLD [135], supported by the ob-
servation that stress granule components co-
aggregate with TDP-43 and FUS [14]. Because the
formation of stress granules might be induced by
glucose deprivation [17], it is conceivable that factors
that lead to glucose starvation, such as high-inten-
sity exercise or caloric restriction, might predis-
pose to stress granule formation and
subsequently to TDP-43/FUS aggregation in ALS
and FTLD. Conversely, T2DM and dyslipidemia
might provide protection by supplying more glucose
or alternate sources of energy, thereby preventing the
formation of stress granules.
2. Changes in the cellular metabolic environment may
alter nucleocytoplasmic transport [69], leading to
increased localization of TDP-43 or FUS to the
cytoplasm, which is a prerequisite step in the formation
of their cytoplasmic inclusions. Furthermore, glucose
or lipid starvation can lead to activation of
AMP-activated protein kinase (AMPK), a major
cellular energy sensor, which is found to be active
in motor neurons of ALS patients and its activity
correlates to the cytoplasmic mislocalization of
TDP-43. Consistently, it has been shown that activation
of AMPK induces cytoplasmic mislocalization of
TDP-43 in motor neuronal cell lines [93, 95]. Rapidly
accumulating evidence shows both T2DM and
dyslipidemia are associated with reduction in
AMPK activity, which was shown to be protective
in genetic models of ALS [28, 91].
3. Finally, prolonged caloric/energy restriction induces
autophagy in cells [114] might, in turn, enhance
protein aggregation. This is supported by the
observation that autophagosome markers, such as
microtubule-associated protein 1A/1B-light chain 3
(LC3), were present adjacent to TDP-43 inclusions
in autopsies from ALS patients [51]. On the
contrary, recent evidence suggests that autophagy is
reduced in obesity and T2DM. Under diabetic
conditions, activation of transforming growth
factor beta and miR-192 reduce autophagy in renal
glomerular cells [40]. Similarly, high fat diet
induced dyslipidemia is known to impair lysosomal
functioning and autophagy [195]. Therefore, it is
likely that these conditions counteract the forma-
tion of autophagosomes, which serve as precursors to
pathological aggregates in ALS/FTLD.
Does altered metabolism counteract effects of
protein aggregation in ALS/FTLD?
An alternate possibility is that the abnormal protein
aggregation in ALS and FTLD causes neurons to become
unusually sensitive to metabolic deprivation, in a way that
renders metabolic perturbations, such as dyslipidemia and
T2DM, beneficial (Fig. 2). There are three major ways in
which this could occur:
1. TDP-43, and other proteins that aggregate in ALS and
FTLD, could be potent regulators of core cellular
metabolic processes. As such, their loss of function
through aggregation might lead to a state of cellular
ATP deficit. Indeed, there is evidence to suggest that
TDP-43 regulates glycolysis in hepatocellular carcin-
oma cell lines [131], and one study demonstrated that
the abnormal localization of TDP-43 to mitochondria
in cells from ALS/FTLD patients leads to the disas-
sembly of the respiratory chain complex I and impairs
mitochondrial oxidative phosphorylation [181]. This
has been corroborated by two more studies showing a
pathological displacement of TDP-43, or its N- and
C-terminal fragments, in mitochondria leading to im-
pairment of mitochondrial functioning [34, 153].
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Hyperglycemia could counteract this by providing
more substrate (glucose) for cellular glucose metabol-
ism, thereby partially replenishing the ATP deficit.
2. Another possibility is that loss of TDP-43 function
(and/or of other ALS- associated proteins) induces
a Warburg-like state [176] in neurons, causing
neurons to rely on readily available glucose to support
their enhanced glycolysis. Hyperglycemia in T2DM
might thus also help to offset the upregulated
glycolysis caused by this metabolic maladaptation.
3. Finally, high levels of glucose and/or lipids may
counteract the cellular toxicity that arises from
abnormal protein aggregation in ALS/FTLD neurons.
Both wild-type TDP-43 and FUS regulate the expres-
sion of anti-oxidative genes, and their loss of function
may lead to increased cell toxicity by reactive oxygen
species (ROS) [115, 154]. Other evidence suggests that
mitochondrial respiration is decreased in skeletal mus-
cles of patients with T2DM [112]. This decrease in
mitochondrial respiration could directly aid in reducing
the toxicity due to ROS by reducing their production.
In conclusion, there is a plausible biological rationale
for the disease-modifying effect of metabolic disorders in
ALS and FTLD based on the aforementioned hypotheses.
How about other NDDs?
Metabolic dysfunction and other
neurodegenerative disorders
The disease modifying effects of altered metabolism may
not be limited to ALS and FTLD: they may be important
for other NDDs [10, 137].
Huntington’s disease (HD) is a hereditary NDD caused
by elongated CAG repeats in the Huntingtin (Htt) gene
that lead to progressive increases in choreic movements
and to neuropsychiatric dysfunction [146]. It is characterized
by reduced mitochondrial ATP production in patient-
derived lymphoblasts and skeletal muscles [96, 151, 156].
Importantly, a high BMI at the time of HD onset is associ-
ated with slower disease progression [117].
Similarly, patients with advanced Parkinson’s disease (PD),
a movement disorder marked by ɑ-synuclein aggregates in
neurons [87], exhibit unintended weight loss [14, 21], which
Fig. 1 A model of how metabolic processes might contribute to abnormal TDP-43 aggregation in ALS/FTD. TDP-43 is primarily a nuclear protein
that mislocalizes to the cytoplasm of neurons in pathological conditions, such as ALS/ FTD, where it undergoes phosphorylation and
ubiquitination and forms cytoplasmic aggregates. Glucose starvation might contribute to the formation of TDP-43 aggregates by inducing the
formation of stress granules. These stress granules might serve as precursors to TDP-43 inclusions. Similarly, caloric restriction might contribute to
TDP-43 aggregation by triggering auto-phagosomes formation, which might serve as another site for TDP-43 aggregation
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may occur as a consequence of increased resting energy
expenditure [89, 106]. Interestingly, similar to ALS, pre-
morbid T2DM slows the progression of PD [31, 99].
Finally, metabolic factors also modify the course of Alz-
heimer’s disease (AD), the most common form of
late-onset dementia, which is characterized by synaptic and
neuronal loss and by the formation of β-amyloid plaques
and neurofibrillary tau tangles in neurons [178]. While
obesity in mid-life is associated with an increased risk of
AD [85, 184], a higher BMI later in life, and slower BMI de-
cline after onset of AD and slow disease progression [71].
Conclusions and future directions
In conclusion, the current clinical literature suggests that
metabolic factors, such as BMI, diet and exercise, and
metabolic disorders, such as T2DM and dyslipidemia,
have a disease-modifying effect in ALS and potentially in
FTLD (Table 1). These disease-modifying effects may be
linked to the involvement of ALS and FTLD-related pro-
teins in cellular and whole body metabolism (Table 2).
However, altered metabolic pathways may also stimulate
the formation of characteristic protein aggregates in ALS
and FTLD (Fig. 1) or could modulate their downstream
toxicity (Fig. 2).
It is imperative that future clinical studies of these dis-
eases are carefully designed to reach conclusive answers.
Studies on the effect of T2DM, dyslipidemia and BMI
on ALS disease course should be prospective and should
adjust for their individual and combined effects, as T2DM,
dyslipidemia, and obesity are often co-morbid. Additional
confounding factors, such as gender, ethnicity, diet,
smoking, other vascular co-morbidities, and medications
should be accounted for. It will also be important to
correlate parameters of disease progression in ALS (e.g.,
the ALS-FRS) to those in metabolic disorders (e.g., serial
measurements of HbA1c and lipid profile). Furthermore,
it will be crucial to assess cognitive function when
studying the effects of metabolic disorders on ALS
because there may be different effects of metabolic
disorders on motor vs. cognitive parameters [75, 76].
Fig. 2 TDP-43 aggregation and defective neuronal glucose metabolism. Loss of TDP-43 function, caused by its abnormal aggregation in neurons,
can potentially lead to defective glycolysis and to defects in the TCA cycle or electron transport chain, leading to decreased ATP levels.
Additionally, TDP-43 loss of function might induce a Warburg effect in neurons, increasing their reliance on glycolysis for ATP production. Finally,
TDP-43 aggregation can lead to increased production of reactive oxygen species (ROS). Type 2 diabetes mellitus (T2DM) can be beneficial in each
of these pathogenic mechanisms; hyperglycemia in T2DM provides readily available fuel for glucose metabolism and can also meet the increased
requirement of glucose in neurons as a result of the Warburg effect, and it can counter ROS by replenishing levels of the anti-oxidant glutathione
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Finally, the disease-modifying effects of T2DM, dyslipid-
emia and BMI should be studied in more detail in patients
with FTLD.
The recent development of autopsy brain banks for NDDs
provides an excellent resource with which to study the ef-
fects of metabolic factors and dysfunction on the neuro-
pathological pathways affected by ALS and FTLD. Through
carefully designed clinicopathological studies, the extent and
distribution of TDP-43 pathology in specific brain regions
may be compared between ALS/FTD patients, who have or
do not have a particular metabolic disorder. Similarly, a
comparison of downstream pathways, such as those in-
volved in neuronal loss, astrogliosis, autophagy, microglial
activation, mitochondrial respiration, AMPK activity, and
ROS levels, might provide important clues as to whether the
effects of metabolic disorders on ALS/FTLD occur prior to
or after protein aggregation occurs.
Most studies that have investigated a role for metabolic
factors in the pathology of ALS/FTLD were performed in
vivo in animal models, which have supported and
advanced clinical findings in humans, where it is more
difficult to control for various factors. Immortalized
cancer cell lines and in neural stem cells are also excellent
models to study; however, they can show metabolic adapta-
tions that complicate interpretation of data derived from
them [23, 68]. Other systems that may be excellent for
studying metabolic effects in real time include alternative
ex vivo systems, such as organotypic slice culture models
[88], induced pluripotent stem cells (iPSCs)-derived neu-
rons [108] or long-term complex neuronal cultures [159].
At the same time, they allow for genomic, transcriptomic,
proteomic, metabolomics, and epigenetic analyses. Finally,
we need to better understand how the nuclear localization,
aggregation, and phosphorylation of TDP-43 and FUS
might be influenced by altered metabolic states, such as
hyperglycemia and dyslipidemia, and how these states
might protect neurons from damage. We also need to
experimentally investigate the role of astrocytes and
microglia in the potential disease-modifying effect of
metabolic disorders in ALS and FTLD.
Conclusion
In conclusion, we have presented hypotheses that bridge
the basic and clinical lines of research related to the dis-
ease-modifying effect of metabolic factors and disorders in
ALS/FTLD. This review may serve as an inspiration for
translationally oriented studies into the topic, which has
important implications for prevention and treatment of
ALS/FTLD.
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